This update, planned in partnership with the American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy, provides the hepatology specialist with guidance on endoscopic innovations and challenges in managing patients with liver diseases.
This workshop highlights the offerings of the Liver Fellow Network (LFN) with presentations of the most impactful posts by content creators in the featured core series: Clinical Pearls, Evidence Corner, Why? Series, and Back to Basics. The session also features an inaugural presentation from the new Guidelines series. A discussion moderated by LFN fellow leads and faculty chairs follows each presentation. Through these discussions, the moderators and panelists aim to critically appraise the literature highlighted in the presentations (Evidence Corner, Why? Series); and discuss challenges and pearls in the diagnosis and management of patients with liver disease (Clinical Pearls, Guidelines, Back to Basics). Presenters intend for workshop attendees to leave with an enhanced understanding of the strengths and limitations of presented literature, and increased knowledge of the multitude of diagnostic and management options for persons with liver disease.
Hepatitis B virus (HBV)–related hepatocellular carcinoma (HCC) remains the most common complication of chronic HBV infection. Treatment with HBV antiviral therapy has been shown to reduce the risk of HCC but does not completely eliminate it. Currrent screening and surveillance strategies that require the use of abdominal ultrasound, with or without alpha-fetoprotein testing, are suboptimal. Therefore, novel approaches to HCC screening and surveillance are urgently needed in clincial practice.
Experts review recommendations from current American Association for the Study of Liver Diseases guidelines and discuss methods to refine screening and surveillance strategies for persons living with chronic HBV infection. Speakers also highlight novel biomarkers and imaging-based modallities that show promise for improving early detection of HCC in persons living with chronic HBV infection. Data from clinical studies are reviewed and translated into practice points for the clinician.
Artificial intelligence (AI) tools are increasingly integrated into hepatology clinical practice and training (eg, ambient scribes/note drafting in clinic, chart summarization on consult services, and AI–enabled platforms that synthesize evidence for point-of-care questions). While these tools may accelerate access to knowledge, they also introduce educational and professional risks: over-reliance that undermines core clinical skill acquisition; uncritical acceptance of AI–generated recommendations; and evolving boundaries for AI use in scholarship.
This session—presented as a partnership between the Clinical Informatics and Digital Health Special Interest Group and the Training and Workforce Committee—is a highly practical conversation focused on how faculty should incorporate AI into hepatology education while strengthening trainee reasoning, and what guardrails are needed to help trainees and educators use AI responsibly in clinical education.
In multidisciplinary settings—such as transplant selection meetings, tumor boards, and daily rounds—time is limited yet decisions are critical. How do you present a complex patient’s story concisely without losing essential details? Join seasoned experts for an interactive, informal roundtable discussion on strategies to streamline case presentations while maintaining clinical accuracy and impact. Through real-world examples and practical tips, participants learn to communicate effectively across diverse teams and disciplines.
Difficult conversations are an inevitable part of hepatology practice—whether discussing prognosis, disease progression, goals of care, or transplant candidacy. These discussions can be emotionally charged and complex, requiring both clinical expertise and communication finesse. Join hepatology leaders who share practical frameworks, real-world strategies, and tips for fostering trust and clarity during these critical conversations. This case-based, interactive session encourages open dialogue and peer-to-peer learning.
Join us for an engaging session dedicated to exploring the emerging role of incretin therapy in women with liver disease. Led by specialists in hepatology and metabolic syndrome, this discussion synthesizes the latest evidence, clinical considerations, and gender-specific factors that influence the use of incretin-based treatments. Faculty present valuable insights into how these therapies can positively affect liver health, metabolic profiles, and overall outcomes among women. Speakers also examine the role of incretins across the reproductive lifespan—including during childbearing years, in polycystic ovary syndrome, and at menopause—highlighting their significance in women's unique physiological contexts. The multidisciplinary faculty aim to deepen understanding of personalized treatment strategies in this evolving field.
Expert facutly review important considerations and updates regarding the management of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), intrahepatic cholestasis of pregnancy (ICP), and autoimmune hepatitis (AIH) in pregnancy through case-based discussion. The PBC case highlights the approach to preconception counseling of an individual on second-line PBC therapy. The ICP case highlights the association of chronic liver disease with ICP, the relevance of genetic testing, and approaches to management from ursodiol to novel secondary treatments including rifampicin and ileal bile acid transporter (IBAT) inhibitors. The AIH case focuses on key considerations across preconception, pregnancy, and postpartum periods including risk stratification, medication safety, and strategies to optimize maternal and fetal outcomes.
Accurate identification of fibrotic metabolic dysfunction–associated steatohepatitis (MASH) is critical for risk stratification, treatment selection, and referral. Liver biopsy, however, is neither feasible nor appropriate for most patients. Faculty provide a practical, case-based discussion of noninvasive approaches to detecting fibrotic MASH including serum-based scores, elastography, and emerging biomarkers. Speakers emphasize test selection, interpretation in real-world practice, common pitfalls, and strategies for integrating noninvasive tools into efficient clinical workflows across diverse patient populations.
Early identification of persons at risk for fibrotic metabolic dysfunction–associated steatohepatitis (MASH) remains a major gap in care despite the availability of validated noninvasive tools. Presenters examine how electronic health record (EHR)–enabled strategies can be used to systematically identify, risk stratify, and triage patients with suspected MASH in real-world clinical settings. Topics include EHR–based case finding algorithms, automated fibrosis risk scores, clinical decision support, and referral pathways, as well as practical challenges related to workflow integration, equity, and implementation across diverse practice environments.